{
  "documentMetadata": {
    "title": "Oroya Fever, Verruga Peruana, South American Bartonellosis",
    "lastUpdated": "2024-04-24",
    "sourceFile": "Oroya Fever, Verruga Peruana, South American Bartonellosis.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "South American Bartonellosis (aka Carrion's Disease) is a bacterial infection caused by Bartonella bacilliformis.",
        "Transmitted by nocturnal sand flies",
        "Endemic in inter-Andean valleys between 500-3200 meters elevation exclusively in Peru and Ecuador.",
        "Epidemiology: PloS Negl Trop Dis 6(10):e1819, 2012",
        "Biphasic illness. The two stages of the disease are driven by the disease pathogenesis:",
        "  - Oroya Fever is the acute initial phase: febrile illness with positive blood cultures; reflects initial bacteremia with infection of erythrocytes and endothelial cells",
        "    - When critical mass reached, massive hemolysis can occur",
        "    - 1/3 of patients suffer opportunistic infection due to suppression of CD4 lymphocytes",
        "    - Untreated, mortality can reach 40%",
        "  - Verruga peruana (Peruvian wart) is the late cutaneous manifestation; reflects infection of endothelial cells stimulates new vessel formation with subsequent appearance of vascular skin papules and nodules"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Bartonella bacilliformis"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Oroya fever: Intra-erythrocytic bacilli visible on giemsa-stained blood film (36%)",
        "Positive blood cultures: Grows slowly over 1-2 weeks in blood cultures and requires special agar and lower incubation temperature",
        "IFA ultimately positive in 86%",
        "Blood PCR is increasingly available",
        "Verruga peruana: Diagnosis is largely clinical. Can do skin biopsy if in doubt."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Treatment suggestions based on observational studies and case reports. No clinical trial data available",
        "Oroya fever, adults:",
        "  - Uncomplicated, adult: Ciprofloxacin 500 mg po bid x 14 days. Can be combined with Ceftriaxone 1 gm IV once daily for more severe infections.",
        "  - Complicated, more severe infection, adult:",
        "    - Chloramphenicol 50-75 mg/kg/day (max 3 gm) po or IV in 4 divided doses x 14 days in combination with Ceftriaxone 1 gm IV once per day x 10-14 days",
        "Verruga peruana, adult:",
        "  - Uncomplicated: Azithromycin 500 mg po once daily x 7 days",
        "  - Complicated: Ciprofloxacin 500 mg po/IV bid x 7-10 days",
        "  - Note: Chloramphenicol is not active",
        "Oroya fever, children:",
        "  - Uncomplicated: Ciprofloxacin 20 mg/kg po in 2 divided doses x 14 days (max 1 gm/day)",
        "  - Complicated/severe: Chloramphenicol 50-75 mg/kg/day (max 2 gm/day), po/IV, in 4 divided doses x 10-14 days in combination with Ceftriaxone 50-75 mg/kg (max 1 gm/day) IV once daily x 10-14 days",
        "Verruga peruana, pregnancy: Azithromycin 500 mg/kg po once daily x 7 days",
        "Verruga peruana, children:",
        "  - Azithromycin 10 mg/kg (max 500 mg/day) po once daily x 7 days",
        "  - Ciprofloxacin 20 mg/kg (max 1 gm/day) po in 2 divided doses x 14 days"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "None"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Poor activity reported: Vancomycin, Clindamycin, aminoglycosides, Imipenem-cilastatin",
        "Treatment alternatives discussed in: Intl J Antimicrob Agents 44:16, 2014",
        "General references: Parasit Vectors 2019; 12:141; Pediatrics 2011;128:e1034"
      ]
    }
  ]
}